IP Library › Granted Patent US 12,540,176
Granted Patent B2
US 12,540,176 · App. 18/295,193 · Granted Feb 3, 2026

True human antibody specific for interleukin 1 alpha

Inventors: John Simard (Austin, TX); Sushma Shivaswamy (Austin, TX); Galina Kuzmicheva (Austin, TX)
Assignee: XBIOTECH INC.
C07K16/245C07K2317/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,540,176
App. No.
18/295,193
Granted
Feb 3, 2026
Kind
B2
Abstract

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Claims (2)

1 . A pharmaceutical composition comprising a purified human monoclonal antibody that specifically binds to interleukin 1 alpha (IL-1α), and comprises a light chain variable region amino acid sequence comprising a CDR having the amino acid sequence of SEQ ID NO: 3, a CDR having the amino acid sequence WAS, and a CDR having the amino acid sequence of SEQ ID NO:5, and a heavy chain variable region amino acid sequence comprising a CDR having the amino acid sequence of SEQ ID NO:6, a CDR having the amino acid sequence of SEQ ID NO:7, and a CDR having the amino acid sequence of SEQ ID NO:8.

2 . The pharmaceutical composition of claim 1 , wherein the light chain variable region has the amino acid sequence of SEQ ID NO:1, and the heavy chain variable region has the amino acid sequence of SEQ ID NO:2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2023
From: SIMARD, JOHN; SHIVASWAMY, SUSHMA; KUZMICHEVA, GALINA
To: XBIOTECH INC.
Reel/Frame 063232/0917 →
Priority Claims (1)
CA 3095675 · Oct 7, 2020 · national
Continuity (2)
Continuation PCTCA2021051380 · Oct 4, 2021
Related Publication 20230322915A1 · Oct 12, 2023
References Cited (91)
US 4634664A · Oestberg · 1987 [cited by applicant]
US 4965198A · Yamasaki et al. · 1990 [cited by applicant]
US 5034316A · Weisbart et al. · 1991 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5231024A · Moeller et al. · 1993 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5654407A · Boyle et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5792838A · Smith et al. · 1998 [cited by applicant]
US 5795967A · Aggarwal et al. · 1998 [cited by applicant]
US 5932188A · Snow et al. · 1999 [cited by applicant]
US 5959085A · Garonne et al. · 1999 [cited by applicant]
US 6090382A · Salfeld et al. · 2000 [cited by applicant]
US 6140470A · Garen et al. · 2000 [cited by applicant]
US 6623736B2 · Tobinick · 2003 [cited by applicant]
US 7718674B2 · Aberg · 2010 [cited by applicant]
US 8398966B2 · Wu · 2013 [cited by applicant]
US 20030026806A1 · Witte et al. · 2003 [cited by applicant]
US 20030040617A9 · Rosen et al. · 2003 [cited by applicant]
US 20030175832A1 · Marton · 2003 [cited by applicant]
US 20030232054A1 · Tang et al. · 2003 [cited by applicant]
US 20040097712A1 · Varnum · 2004 [cited by applicant]
US 20040185514A1 · Frostegard · 2004 [cited by applicant]
US 20050054019A1 · Michaud et al. · 2005 [cited by applicant]
US 20050147603A1 · Smith et al. · 2005 [cited by applicant]
US 20050276807A1 · Skurkovich · 2005 [cited by applicant]
US 20060127407A1 · Chen · 2006 [cited by applicant]
US 20060159775A1 · McGrath · 2006 [cited by applicant]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20080050310A1 · Ebens, Jr. et al. · 2008 [cited by applicant]
US 20090123415A1 · Simard · 2009 [cited by applicant]
US 20090191149A1 · Simard · 2009 [cited by applicant]
US 20090215992A1 · Wu · 2009 [cited by applicant]
US 20090258070A1 · Burnier · 2009 [cited by applicant]
US 20090291081A1 · Hsieh · 2009 [cited by applicant]
US 20090298096A1 · Simard · 2009 [cited by applicant]
US 20100040574A1 · Simard · 2010 [cited by applicant]
US 20100047239A1 · Wu · 2010 [cited by applicant]
US 20100068212A1 · Simard · 2010 [cited by applicant]
US 20100221179A1 · Hsieh · 2010 [cited by applicant]
US 20110008282A1 · Simard · 2011 [cited by applicant]
US 20110142761A1 · Wu · 2011 [cited by applicant]
US 20110311547A1 · Simard · 2011 [cited by applicant]
US 20120015384A1 · Simard · 2012 [cited by applicant]
US 20120045444A1 · Simard · 2012 [cited by applicant]
US 20120231012A1 · Simard · 2012 [cited by applicant]
US 20120251548A1 · Simard · 2012 [cited by applicant]
US 20130039921A1 · Simard · 2013 [cited by applicant]
US 20130078258A1 · Simard · 2013 [cited by applicant]
US 20130195877A1 · Simard · 2013 [cited by applicant]
US 20130280253A1 · Hsieh · 2013 [cited by applicant]
US 20130287788A1 · Simard · 2013 [cited by applicant]
US 20140086933A1 · Simard · 2014 [cited by applicant]
AU 2007202323 · 2007 [cited by applicant]
CA 2426384 · 2003 [cited by applicant]
EP 0267611 · 1993 [cited by applicant]
EP 0659766 · 1995 [cited by applicant]
JP 2004285057 · 2004 [cited by applicant]
WO 9524917 · 1995 [cited by applicant]
WO 9635719 · 1996 [cited by applicant]
WO 0233094 · 2002 [cited by applicant]
WO 2004100987 · 2004 [cited by applicant]
WO 2006001967 · 2006 [cited by applicant]
WO 2007015128 · 2007 [cited by applicant]
WO 2007039552 · 2007 [cited by applicant]
WO 2007120828 · 2007 [cited by applicant]
WO 2007132338 · 2007 [cited by applicant]
WO 2007135546 · 2007 [cited by applicant]
WO 9006371 · 2009 [cited by applicant]
WO 2009148575 · 2009 [cited by applicant]
WO 2010030979 · 2010 [cited by applicant]
WO 2010087972 · 2010 [cited by applicant]
WO 2011159976 · 2011 [cited by applicant]
WO 2012027324 · 2012 [cited by applicant]
WO 2012135812 · 2012 [cited by applicant]
WO 2013043973 · 2013 [cited by applicant]
WO 2014055541 · 2014 [cited by applicant]
WO 2014055544 · 2014 [cited by applicant]
WO 2020176738 · 2020 [cited by applicant]
WO 2022073103 · 2022 [cited by applicant]
WO 2022073104 · 2022 [cited by applicant]
WO 2022073105 · 2022 [cited by applicant]
WO 2022105817 · 2022 [cited by applicant]
Miossec, P.: “Anti-interleukin 1 alpha autoantibodies,” Ann Rheum Dis, 2002, 61:577-579. [cited by applicant]
Fleischmann, Roy M., A phase II trial of lutikizumab, an anti-interleukin-1alpha/beta dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis, Arthritis & Rheumatology, Jul. 2019, vol. 71, No… [cited by applicant]
Dinarello, Charles A.: “Modalities for reducing interleukin 1 activity in disease” TIPS, May 1993, vol. 14:155-159. [cited by applicant]
Garrone, P. et al.: “Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1alpha specific inhibitor,” Molecular Immunology, 1996, vol. 33, No. 78:649-658. [cited by applicant]
Satoh, H. et al.: “Characterization of anti-IL-1alpha autoantibodies in the sera from healthy humans,” Immunopharmacology, 1994, vol. 27:107-118. [cited by applicant]
Saurat, Jean-Hilaire et al.: Anti-interleukin-1alpha autoantibodies in humans: Characterization, isotype distribution, and receptor-binding inhibition—Higher frequency in Schnitzler's syndrome (urticaria and macroglobul… [cited by applicant]
Kasahara, T. et al.: “Preparation and characterization of polyclonal and monoclonal antibodies against human interleukin 1 alpha (IL 1 alpha),” The Journal of Immunology, Mar. 1987, vol. 138, No. 6:1804-1812. [cited by applicant]
Hong, David S. et al: “MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study,” Lancet Oncol, 2014, vol. 15:656-66. [cited by applicant]